US36870H1032 - Common Stock
GNLX stock results show that Genelux missed analyst estimates for earnings per share the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Genelux (NASDAQ:GNLX) just reported results for the first quarter of 2024.Genel...
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates...
GNLX stock results show that Genelux missed analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Genelux (NASDAQ:GNLX) just reported results for the fourth quarter of 2023.Gene...
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update...
Read about Genelux (GNLX)'s filing of a prospectus for a mixed shelf offering to raise up to $300M.
HC Wainwright initiated coverage of Genelux (GNLX) with a buy rating, highlighting the potential of its lead oncolytic virus Olvi-Vec in the treatment of tumors. Read more here.
Genelux (GNLX) has received fast-track status from the FDA for its Olvi-Vec program in the treatment of platinum resistant/refractory ovarian cancer. Read more here.
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer...
- Expanded executive team as Lourie Zak appointed Chief Financial Officer - - Extended clinical focus on systemic administration in small cell lung...
Genelux Corporation (GNLX) 10% owner, Aladar Szalay, discloses the sale of 5,704 shares for $110,637, adding to previous insider trades.
Genelux Corporation (GNLX) 10% owner, Aladar Szalay, sells nearly $1M worth of shares, as insider trading activity continues on the stock.
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END
Genelux (GNLX) 10% owner Szalay Aladar continued to offload his stake in the biopharmaceutical company, with 75,690 shares sold at $25.4885 for total transactio
Genelux director continues to sell stake in biopharmaceutical company, with a total of 28 sells out of 34 insider trades in the past 3 months.
Genelux (GNLX) stock falls as director Szalay Aladar sells off his direct and indirect stake in the company, disposing of 62,459 shares.
WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today...